hand 777 app download latest version
NoneThat which brings us together at the library
‘Overdue’ Lebanon ceasefire must bring lasting solution to crisis, says PMThe stock market has witnessed significant gains in 2024, with the S&P 500 up over 20% year to date. But will this momentum continue into the new year? Stephen 'Sarge' Guilfoyle joined TheStreet to discuss his market outlook for 2025. Related: Top Wall Street analyst unveils unexpected S&P 500 price target for 2025 Full Video Transcript Below: CONWAY GITTENS: So tell me, what are your overall expectations for the stock market overall in 2025? Do you expect another year of growth. I know we're like double digits with S&P 500. What's still like 20% up year to date? STEPHEN GUILFOYLE: So far. Yeah, I would expect that to slow down somewhat, especially if interest rates can't be tamed. If the bond market, like I said, takes control of the long end of the yield curve away from the Fed and that and and prices. I don't five year debt out to 30 year debt appropriately. Well, then of course, that's going to slow the slow the economy down because then corporations won't be able to service their debt as cheaply. They won't be able to roll over as much of their debt. They'll actually have to pay it off. The same would be for the U.S. government unless they unless they put out all their debt in 30, 60, and 90 day treasuries, which is kind of ridiculous. But that's the only way the Fed could control their borrowing costs. I know they're supposed to be independent. They would not be independent. If they were doing that by the federal government. But because of these factors, I think that if borrowing costs can't be contained moving forward, that will obviously start on corporations. And it will obviously slow down government spending even if the two candidates, whoever wins, want to be irresponsible. CONWAY GITTENS: Tell me, what then is the biggest risk facing the market in 2025, in your view? STEPHEN GUILFOYLE: The largest risk would be a hot war involving the United States. I mean, would if the United States were to be sucked into a war in Asia with China, which is another superpower, or if they would be sucked in, somehow drawn into this war in Eastern Europe due to NATO being an alliance where they all have to defend each other, or if the United States gets sucked into combat in the back in the Middle East where we've been for so long and we're finally out of it, I think that would be a black swan event if the United States got into a hot war with somebody that could punch back, I think that would be a devastating blow to the U.S. economy and to the market. Watch More Interviews:
Cowboys G Zack Martin, CB Trevon Diggs out vs. CommandersMinisters told ‘incompetence’ at Met Office led to underestimation of Storm Bert
NAPLES, Fla. (AP) — Narin An handled the windy conditions with a hot putter on Thursday, making four straight birdies around the turn and finishing with an 8-under 64 for a one-shot lead in the CME Group Tour Championship. At stake for the 60-player field is a $4 million prize to the winner, the largest single-day payoff in women's golf. Nelly Korda already has won more than that during her sterling season of seven wins. Now she faces an eight-shot deficit over the next three days at Tiburon Golf Club if she wants to end her year in fitting fashion. Korda, coming off a victory last week, couldn't make amends for her three bogeys and had to settle for an even-par 72. She has come from behind in four of her victories, and still has 54 holes ahead of her. But it has made the task that much tougher. Everything felt easy for An, a 28-year-old from South Korea who has never won on the LPGA and has never cracked the top 10 in any of the 16 majors she has played. “Today my putt really good,” An said. “The speed was good and the shape was good. I just try to focus a little bit more.” She had a one-shot lead over Angel Yin, who shot 30 on the back nine, including an eagle on the par-5 17th hole that most players can easily reach in two. Former U.S. Women's Open champion Allisen Corpuz and Marina Alex were at 66, with Lydia Ko leading the group at 67. Despite the wind so typical along the Gulf Coast of Florida, 27 players — nearly half the field — shot in the 60s. “It's a good head start for the big ol' prize we get at the end of the week,” Yin said. Whoever wins this week is assured of breaking the 17-year-old LPGA record for most money earned in season. The record was set by Lorena Ochoa in 2007 at $4,364,994, back when the total prize money was about half of what it is now. Ochoa earned $1 million for winning the Tour Championship in 2007. The opening round followed a big night of awards for the LPGA Tour, where Korda officially picked up her first award as player of the year, which she clinched earlier this month . Ko was recognized for her big year, highlighted by an Olympic gold medal that put her into the LPGA Hall of Fame. She regained plenty of focus for the opening round on a course where she won just two years ago. “The course isn't easy,” Ko said. “I set a goal of shooting 3 under today, and somebody shot 8 under. I was like, ‘OK, maybe I need to make a few more birdies.’ It's a course that can get away from you as much as you can shoot some low scores, so I’m just trying to stick to my game plan and go from there.” Also in the group at 67 was Albane Valenzuela of Switzerland, already celebrating a big year with her debut in the Solheim Cup and her first appearance in the Tour Championship. She made a late run at her first LPGA title last week at Pelican Golf Club, and kept up her form. And she can see the finish line, which is appealing. “I everyone is looking at that $4 million price tag,” Valenzuela said. “I try not to look too much at the result. I feel like in the past I’ve always been stuck on results, and ultimately all I can do is control my own round, my own energy, my own commitment. “It's the last week of the year. It’s kind of the bonus week. No matter what, everyone is having a paycheck.” ___ AP golf: https://apnews.com/hub/golf The Associated PressScottsdale, Arizona, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Hosted at the prestigious Fairmont Princess in Scottsdale, this year's MedSpa Pro Meeting brought together pacesetting voices in medical aesthetics under the guidance of industry pioneers and co-chairs Barry DiBernardo, MD, Jason Pozner, MD, and Joseph Russo, MD. Over three intensive days, participants immersed themselves in a wealth of cutting-edge, comprehensive content that spanned advanced injection techniques, emerging technologies, and business management strategies. Program highlights included an exclusive Head-to-Head Anatomy Masterclass led by preeminent anatomist Sebastian Cotofana, MD, PhD, and an innovative Weight Loss Track spearheaded by Johnny Franco, MD. Complementing these sessions, expertise-driven curricula featured a dedicated Aesthetician Track and Master Injector Live Injection Program. Beyond the core curriculum, expert-led panel discussions explored today's most pressing aesthetic medicine topics while market-leading brands showcased game-changing products and services in the exhibition space. Together, these experiences equipped participants with fresh perspectives, practical insights, valuable partnerships, and lasting connections, empowering them to elevate their clinical and personal success. MedSpa Pro's rebranding represents expanding pathways for advancing this booming specialty. "As we embrace the next chapter in aesthetic medicine, we are excited to unveil our new identity as MedSpa Pro," stated Doreen Brown, CEO of Informa Connect Medical Division. "This evolution reflects our commitment to keeping pace with our ever-evolving industry and serving our expanding community through gold-standard training and unmatched networking opportunities." MedSpa Pro's refined brand identity will roll out in the coming months as the company prepares for a breakthrough 2025. Among exciting new initiatives, next year introduces specialized training opportunities led by the distinguished Dr. Russo and fellow acclaimed experts, strengthening the organization's position as the foremost resource in medical aesthetics. Aesthetic medicine providers, medical spa professionals, and industry stakeholders can mark their calendars for the 3rd Annual MedSpa Pro Meeting, set to take place at the iconic Boca Raton resort in November 2025. Further details about upcoming programs will be announced soon; in the meantime, please visit MedSpa Pro's LinkedIn profile for updates. ### MedSpa Pro serves as the leading educational platform for medical aesthetics professionals, delivering targeted education, tailored training, and strategic networking opportunities across the industry. Through its premier conference and progressive initiatives, the organization connects enterprising practitioners with renowned experts to advance excellence in aesthetic medicine. MedSpa Pro is part of the Informa Connect Medical Division, a global force in medical education across the entire healthcare ecosystem. Aly Vazquez MedSpa Pro aly.vazquez@informa.com(The Center Square) - California Republicans flipped a second seat in the state legislature, nearly three weeks after the general election. Republicans noted the party had not flipped a State Senate seat during a presidential election since 1980. President-elect Trump has won 38.2% of votes counted thus far in California, more than Senator Mitt Romney, R-Utah, in 2012, and former senator John McCain, R-Ariz., in 2008, but less than former president George W. Bush in 2004, who won 44.4% of the votes in California. Steven Choi, a former Republican member of the State Senate, narrowly pulled out a victory in the Orange County district nearly three weeks after the general election. The incumbent Democrat, State Sen. Josh Newman, D-Fullerton, lost a recall in 2018 due to backlash against a gas tax increase he voted for, won office elsewhere after redistricting in 2020, and introduced a measure to limit future recalls. But California Democrats blame Newman’s loss on one of the state’s most powerful unions funding Choi to send a message regarding Newman’s quashing of a bill to add rights for the workers at the University of California system into the state constitution. KCRA reports the American Federation of State, County and Municipal Employees 3299, which represents approximately 30,000 workers across the ten-campus University of California system, independently spent $3.5 million opposing Newman and helping Choi. According to Follow the Money, a project of Open Secrets, Newman raised a reported $7 million thus far on his 2024 election compared to a reported $564,193 thus far for Choi. “Instead of spending time, effort and energy helping Democrats win congressional races, [AFSCME] supported a supporter of Donald Trump,” said Sen. President Pro Tem Mike McGuire to CalMatters. “They supported a pro-Trump Republican who is anti worker.” AFSCME 3299 is a chapter of one of the most powerful, generally Democratic-aligned,unions in the state. Public sector unions are seen as the most powerful force in California politics. While private sector unions veered heavily towards president-elect Trump in the 2020 election, public sector unions — outside unions for first-responders such as firefighters or police — generally supported Harris. A rift between Democrats and traditionally very Democratic-friendly public sector unions in California — the most populous state in the nation and a political bedrock for the Democratic party could create a significant challenge for the party as it regroups after the 2024 election. Three weeks after the election, many races are uncalled, as about 183,000 ballots remain to be processed, only about 5,300 of which were mail-in ballots that arrived after Election Day. Nearly two weeks ago, when 1.7 million ballots remained to be processed, California Secretary of State Shirley Weber told attendees of a virtual press conference that she and the state’s elections officials “take pride in the fact we are not rushed.”
Larson Financial Group LLC decreased its holdings in Viper Energy, Inc. ( NASDAQ:VNOM – Free Report ) by 11.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,843 shares of the oil and gas producer’s stock after selling 250 shares during the quarter. Larson Financial Group LLC’s holdings in Viper Energy were worth $83,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also recently bought and sold shares of VNOM. Farther Finance Advisors LLC raised its stake in shares of Viper Energy by 328.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 587 shares of the oil and gas producer’s stock valued at $26,000 after acquiring an additional 450 shares during the period. GAMMA Investing LLC increased its holdings in Viper Energy by 208.1% in the 3rd quarter. GAMMA Investing LLC now owns 681 shares of the oil and gas producer’s stock valued at $31,000 after purchasing an additional 460 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Viper Energy in the second quarter valued at about $36,000. ORG Partners LLC lifted its stake in shares of Viper Energy by 962.3% during the second quarter. ORG Partners LLC now owns 2,815 shares of the oil and gas producer’s stock worth $107,000 after purchasing an additional 2,550 shares in the last quarter. Finally, Plato Investment Management Ltd boosted its position in shares of Viper Energy by 119.2% in the second quarter. Plato Investment Management Ltd now owns 2,834 shares of the oil and gas producer’s stock worth $106,000 after buying an additional 1,541 shares during the period. 87.72% of the stock is owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Several brokerages recently commented on VNOM. Piper Sandler raised their target price on Viper Energy from $61.00 to $64.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Roth Mkm boosted their target price on shares of Viper Energy from $46.00 to $53.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. StockNews.com downgraded shares of Viper Energy from a “hold” rating to a “sell” rating in a research note on Tuesday, November 5th. Truist Financial lifted their price target on shares of Viper Energy from $57.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Bank of America assumed coverage on shares of Viper Energy in a research report on Tuesday. They issued a “buy” rating and a $64.00 price objective for the company. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.78. Viper Energy Stock Performance VNOM stock opened at $54.11 on Friday. The stock’s 50 day simple moving average is $51.44 and its 200 day simple moving average is $44.90. Viper Energy, Inc. has a 12-month low of $29.03 and a 12-month high of $56.76. The firm has a market cap of $10.19 billion, a P/E ratio of 23.22 and a beta of 1.72. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.25. Viper Energy ( NASDAQ:VNOM – Get Free Report ) last issued its earnings results on Monday, November 4th. The oil and gas producer reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.02. The firm had revenue of $209.59 million for the quarter, compared to analysts’ expectations of $210.54 million. Viper Energy had a net margin of 24.65% and a return on equity of 6.72%. Viper Energy’s revenue was down 28.5% on a year-over-year basis. During the same quarter last year, the company posted $1.10 earnings per share. As a group, equities research analysts predict that Viper Energy, Inc. will post 2.03 EPS for the current year. Viper Energy Announces Dividend The business also recently announced a quarterly dividend, which was paid on Thursday, November 21st. Shareholders of record on Thursday, November 14th were given a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 2.22%. The ex-dividend date of this dividend was Thursday, November 14th. Viper Energy’s dividend payout ratio is presently 51.50%. About Viper Energy ( Free Report ) Viper Energy, Inc owns and acquires mineral and royalty interests in oil and natural gas properties in the Permian Basin, North America. Viper Energy Partners GP LLC operates as the general partner of the company. The company was formerly known as Viper Energy Partners LP and changed its name to Viper Energy, Inc in November 2023. Read More Want to see what other hedge funds are holding VNOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viper Energy, Inc. ( NASDAQ:VNOM – Free Report ). Receive News & Ratings for Viper Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viper Energy and related companies with MarketBeat.com's FREE daily email newsletter .
Unlike scores of people who for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It’s a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It’s all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person’s response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn’t happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It’s not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn’t respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I’m hoping it’s slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press
None
Taylor Swift and Brittany Mahomes' private exchange leaked after controversial Chiefs-Bills momentCash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 3 . Daix (France), New York City, (New York, United States), November 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2024 and its revenues for the first nine months of 2024. Cash and cash equivalents As of September 30, 2024, the Company’s cash and cash equivalents amounted to €13.9 million, compared to cash and cash equivalents at €26.9 million, short-term deposit 4 at €0.01 million, and long-term deposit 5 at €9.0 million as of December 31, 2023. Net cash used in operating activities amounted to (€64.2) million in the first nine months of 2024, compared to (€69.0) million for the same period in 2023 down by 7.0%. R&D expenses, mainly driven by the development of lanifibranor in MASH/NASH, for the first nine months of 2024 amounted to €71.7 million and were down 10.0% compared to the €79.6 million for the first nine months of 2023. The decrease in R&D expenses over the period is primarily due to the temporary voluntary pause in the recruitment of patients in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH/NASH (“NATiV3") following the Suspected Unexpected Serious Adverse Reaction (“SUSAR”) previously reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND Phase 2a combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes (“T2D”). R&D expenses have started to increase as expected in the second half of 2024 following the restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with the NATiV3 for the second half of 2024. Net cash generated from investing activities for the first nine months of 2024 amounted to €8.7 million, compared to (€3.5) million used for the same period in 2023. The change is mostly due to the variation in term deposits between both periods. Net cash generated from financing activities for the first nine months of 2024 amounted to €42.3 million compared to €30.2 million in the same period in 2023. The change is due to (i) the second tranche of €25 million drawn in January 2024 under the unsecured loan agreement granted by the European Investment Bank (“EIB”) with the issue of 3,144,654 warrants to the EIB, and (ii) the issuance on July 18, 2024, of royalty certificates (the “2024 Royalty Certificates”) subscribed by Samsara BioCapital, and existing shareholders BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of €20.1 million. The 2024 Royalty Certificates give the holders thereof the right to an annual payment of royalties equal to 3% of the potential future net sales of lanifibranor, if any, in the United States, the European Union and the United Kingdom over a 14-year term from the date of their issuance 6 . Over the first nine months of 2024, the Company did not record any exchange rate effect on cash and cash equivalents, compared to a negative exchange rate effect of (€0.7) million for the same period in 2023, due to the evolution of the EUR/USD exchange rate. Financial information after closing the accounts On October 14, 2024, the Company announced a multi-tranche equity financing (the “Equity Raise”) of up to €348 million from both new and existing investors 2 . The Company closed the first part of the first tranche of the Equity Raise on October 17, 2024, and issued 34,600,507 new ordinary shares (the “T1 New Shares”) at a price of €1.35 per T1 New Share, and 35,399,481 prefunded warrants to purchase ordinary shares in the Company at an exercise price of €0.01 and a subscription price of €1.34 per new ordinary share and received €94.1 million in gross proceeds (net proceeds approximately €86.6 million). The second part of the first tranche and the second and third tranches of the Equity Raise remain subject to satisfaction of specified conditions, and in particular shareholder approval. On October 14, 2024, the Company also announced that it had amended its license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) CO., LTD. (“CTTQ”). Pursuant to the amendment, if the Company receives commitments from investors to subscribe to an equity raise, in two or three tranches, prior to December 31, 2024, for an aggregate amount of at least €180 million, CTTQ shall pay to the Company (i) $10 million within 30 days of settlement-delivery of the new shares and prefunded warrants in the first tranche of the Equity Raise, (ii) $10 million upon the completion of the second tranche of the Equity Raise and (iii) $10 million upon the publication by the Company of positive topline data announcing that any key primary endpoint or key secondary endpoint of the NATiV3 trial, with any dosage regimen tested in the trial, have been met. Under the terms of the Amendment, the total amount of milestone payments remains unchanged, while the royalties that Inventiva is eligible to receive have been reduced to the low single digits. The signing of the Equity Raise satisfied the condition of receiving commitments for an aggregate amount of at least €180 million and the closing of the first part of the first tranche of the Equity Raise satisfied the condition (i) above. Subsequently, on November 18, 2024, the Company received the first milestone payment of $10 million from CTTQ pursuant to this amendment. Considering its current cost structure and forecasted expenditures and including (i) the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the Equity Raise, and (ii) the first milestone of $10 million (gross proceeds) received under the amendment to the licensing agreement with CTTQ, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 2025 2 . The Company currently expects that the conditions for the closing of the second part of the first tranche of the Equity Raise will be satisfied in December 2024. Considering its current cost structure and forecasted expenditures, the Company estimates that the anticipated receipt of the proceeds (a gross amount of €21.4 million) from the second part of the first tranche of the Equity Raise announced on October 14, 2024 would be sufficient to extend the Company’s ability to finance its operations until middle of the third quarter of 2025. Revenues The Company’s revenues for the first nine months of 2024 amounted to €1.3 million, as compared to €1.9 million for the same period in 2023. *** Next key milestones expected Randomization of the last patient of the NATiV3 Phase 3 clinical trial evaluating lanifibranor in MASH/MASH – expected in the first half 2025 following the anticipated end of screening targeted for the end of the year 2024 Topline results of NATiV3 – expected in the second half of 2026 Upcoming shareholders meeting Shareholders general meeting – December 11, 2024 Upcoming investor conference participation 43 rd Annual J.P. Morgan Healthcare conference – January 13-16, 2025 – San Francisco 13th edition of Degroof Petercam’s virtual healthcare conference – January 21-24, 2025 Upcoming scientific conference participation MASH-TAG – January 9-12, 2025 – Park City Next financial results publication Full-Year 2024 Revenues and cash and cash equivalents : Thursday, February 13, 2025 (after U.S. market close) About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase 3 clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program. The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Important Notice This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, unaudited financial information, forecasts and estimates with respect to Inventiva’s cash resources, the anticipated proceeds from the Equity Raise, completion and timing of the Equity Raise, the satisfaction in part or full of the conditions precedent to closing of the various tranches of the Equity Raise and the timing thereof, and the exercise by the investors of the warrants and pre-funded warrants issued in connection with the Equity Raise, Inventiva’s expectations regarding its collaboration agreement with CTTQ, including the achievement of specified milestones thereunder, forecasts and estimates with respect to Inventiva’s pre-clinical programs and clinical trials, including design, protocol, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase 3 clinical trial with lanifibranor in MASH/NASH, the clinical development of and regulatory plans and pathway for lanifibranor, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva’s product candidates, including lanifibranor, potential regulatory submissions, approvals and commercialization, Inventiva’s pipeline and preclinical and clinical development plans, the potential development of and regulatory pathway for odiparcil, future activities, expectations, plans, growth and prospects of Inventiva and its partners, and business and regulatory strategy, the potential commercialization of lanifibranor and achievement of any sales related thereto, potential payment of royalties and anticipated future performance. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “opportunity”, “possible”, “aim”, and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance, or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment or the ultimate impact on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern, Inventiva’s ability to obtain financing and to enter into potential transactions and Inventiva’s ability to satisfy in part or full the conditions precedent for additional tranches of the Equity Raise and the conditions with respect to CTTQ, and whether and to what extent the Warrants may be exercised and by which holders, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require holds and/or amendments to Inventiva’s clinical trials, Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH/NASH may not be realized and may not support the approval of a New Drug Application, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva’s and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, impacts and potential impacts on the initiation, enrollment and completion of Inventiva’s and its partners’ clinical trials on anticipated timelines and the state of war between Israel and Hamas and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024, as amended on October 14, 2024, the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024, and the Half-Year Report for the six months ended June 30, 2024 on Form 6-K filed with the SEC on October 15, 2024 for other risks and uncertainties affecting Inventiva, including those described under the caption “Risk Factors”, and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Non-audited financial information. 2 Press release of October 14, 2024 3 This estimate is based on the Company’s current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. 4 Short-term deposits were included in the category “other current assets” in the IFRS consolidated statement of financial position and were considered by the Company as liquid and easily available. 5 The long-term deposit had a two year-term, was accessible prior to the expiration of the term with a notice period of 31 days and was considered as liquid by the Company. 6 Press release of July 18, 2024 Attachment Inventiva - PR - Q3 2024 CA Cash - EN - 11 21 2024 - Final
- Previous: hand 777 app
- Next: hand 777 casino login no deposit bonus
